Biocept Aandeel

Biocept Quick Ratio

Delisted

De Snelle Ratio (Zuurtestratio) van Biocept (BIOC) per 11 aug 2026 bedraagt 1,66. In het voorgaande jaar bedroeg Snelle Ratio (Zuurtestratio) 2,64 — een verandering van -37,02% (lager).

Quick Ratio

1,66

YoY

-37,02%

Laatst bijgewerkt:

Snelle Ratio (Zuurtestratio) van Biocept is 2026 1,66 . Snelle Ratio (Zuurtestratio) van Biocept was 2025 2,64 . Het is daarmee -37,02% lager lager dan het jaar ervoor.
Access this data via the Eulerpool API

Biocept Aandelenanalyse

Wat doet Biocept? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is een van de meest populaire bedrijven op Eulerpool.

Veelgestelde vragen over het aandeel Biocept

Snelle Ratio (Zuurtestratio) van Biocept bedraagt 1,66 in 2026.

Snelle Ratio (Zuurtestratio) van Biocept is veranderd van 2,64 naar 1,66, wat een verandering van -37,02% vertegenwoordigt. De waarde is lager dan het vorige jaar.

Op Eulerpool vindt u de volledige historische ontwikkeling van Snelle Ratio (Zuurtestratio) Biocept sinds 2006 – met jaarlijkse waarden, grafieken en gedetailleerde analyse.

De quick ratio meet de kortetermijnliquiditeit van een bedrijf zonder rekening te houden met voorraad.

Een 'goede' varieert per branche en bedrijfsfase. Op Eulerpool kunt u maatstaven direct vergelijken.

Access this data via the Eulerpool API

Hefboom — Biocept

Alle kengetallen — Biocept